What question did this study set out to answer?

To evaluate the LDL-C lowering efficacy of atorvastatin and ezetimibe combination therapy in acute coronary syndrome.

March 15, 2026

Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study

Key Points

To evaluate the LDL-C lowering efficacy of atorvastatin and ezetimibe combination therapy in acute coronary syndrome.
Compared combination therapy with high-intensity atorvastatin alone
Measured LDL-C concentrations at 4 and 12 weeks
Evaluated participant tolerance and treatment goals
Combination therapy resulted in a robust decrease in LDL-C concentrations
Higher proportion of participants achieved LDL-C goals compared to atorvastatin alone
Indicates potential for improved cardiovascular outcomes in ACS

Abstract

Ezetimibe added to high-intensity statin therapy was well tolerated and resulted in an immediate and robust additional decrease in circulating LDL-C concentrations, with a markedly higher proportion of participants achieving LDL-C goals at 4 and 12 weeks. These promising results show that dual therapy started immediately at the diagnosis of ACS has the potential to improve cardiovascular outcomes in ACS.

Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study

Key Points

Abstract

Cite This Study